Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Follicular lymphoma: evolving therapeutic strategies
Brad S. Kahl, David T. Yang
Blood (2016) Vol. 127, Iss. 17, pp. 2055-2063
Open Access | Times Cited: 150

Showing 1-25 of 150 citing articles:

PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas
Aaron M. Goodman, Sandip Pravin Patel, Razelle Kurzrock
Nature Reviews Clinical Oncology (2016) Vol. 14, Iss. 4, pp. 203-220
Closed Access | Times Cited: 416
Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma
Kilannin Krysiak, Felicia Gomez, Brian S. White, et al.
Blood (2016) Vol. 129, Iss. 4, pp. 473-483
Open Access | Times Cited: 161
Targeting the Bcl-2 Family in B Cell Lymphoma
Clare M. Adams, Sean Clark-Garvey, Pierluigi Porcu, et al.
Frontiers in Oncology (2019) Vol. 8
Open Access | Times Cited: 136
From genetics to the clinic: a translational perspective on follicular lymphoma
Sarah Huet, Pierre Sujobert, Gilles Salles
Nature reviews. Cancer (2018) Vol. 18, Iss. 4, pp. 224-239
Closed Access | Times Cited: 121
Nanomedicines for the treatment of hematological malignancies
Anil K. Deshantri, Aida Varela-Moreira, Veronika Ecker, et al.
Journal of Controlled Release (2018) Vol. 287, pp. 194-215
Open Access | Times Cited: 121
Autologous Stem Cell Transplantation for Patients with Early Progression of Follicular Lymphoma: A Follow-Up Study of 2 Randomized Trials from the German Low Grade Lymphoma Study Group
Vindi Jurinović, Bernd Metzner, Michael Pfreundschuh, et al.
Biology of Blood and Marrow Transplantation (2018) Vol. 24, Iss. 6, pp. 1172-1179
Open Access | Times Cited: 84
The EBMT/EHA CAR-T Cell Handbook
Nicolaus Kröger, John G. Gribben, Christian Chabannon, et al.
Springer eBooks (2022)
Closed Access | Times Cited: 55
Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016
Mazyar Shadman, Hongli Li, Lisa M. Rimsza, et al.
Journal of Clinical Oncology (2018) Vol. 36, Iss. 7, pp. 697-703
Open Access | Times Cited: 75
Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study
James R. Cerhan, Brian K. Link, Thomas M. Habermann, et al.
International Journal of Epidemiology (2017) Vol. 46, Iss. 6, pp. 1753-1754i
Open Access | Times Cited: 72
Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper
Antonio Cuneo, Giovanni Barosi, Romano Danesi, et al.
Hematological Oncology (2018) Vol. 37, Iss. 1, pp. 3-14
Open Access | Times Cited: 70
Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure
Sonali M. Smith, James Godfrey, Kwang Woo Ahn, et al.
Cancer (2018) Vol. 124, Iss. 12, pp. 2541-2551
Open Access | Times Cited: 67
Metabolic Tumor Volume in Lymphoma: Hype or Hope?
Heiko Schöder, Craig H. Moskowitz
Journal of Clinical Oncology (2016) Vol. 34, Iss. 30, pp. 3591-3594
Open Access | Times Cited: 65
Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib
Günter Krause, Floyd Hassenrück, Michael Hallek
Drug Design Development and Therapy (2018) Vol. Volume 12, pp. 2577-2590
Open Access | Times Cited: 59
M7‐FLIPI is not prognostic in follicular lymphoma patients with first‐line rituximab chemo‐free therapy
Sandra Lockmer, Weicheng Ren, Marianne Brodtkorb, et al.
British Journal of Haematology (2019) Vol. 188, Iss. 2, pp. 259-267
Open Access | Times Cited: 56
The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma
Juan García Valero, Alba Matas‐Céspedes, Fabián Arenas, et al.
Leukemia (2021) Vol. 35, Iss. 9, pp. 2635-2649
Open Access | Times Cited: 46
Phase II study of tazemetostat for relapsed or refractory B‐cell non‐Hodgkin lymphoma with EZH2 mutation in Japan
Koji Izutsu, Kiyoshi Ando, Momoko Nishikori, et al.
Cancer Science (2021) Vol. 112, Iss. 9, pp. 3627-3635
Open Access | Times Cited: 46
Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development
Andrew Davies, Claude Berge, Axel Boehnke, et al.
Advances in Therapy (2017) Vol. 34, Iss. 10, pp. 2210-2231
Open Access | Times Cited: 55
Oncogenic Rag GTPase signalling enhances B cell activation and drives follicular lymphoma sensitive to pharmacological inhibition of mTOR
Ana Ortega-Molina, Nerea Deleyto-Seldas, Joaquim Carreras, et al.
Nature Metabolism (2019) Vol. 1, Iss. 8, pp. 775-789
Open Access | Times Cited: 49
Duodenal-Type Follicular Lymphoma: A Clinicopathologic Review
Etan Marks, Yang Shi
Archives of Pathology & Laboratory Medicine (2018) Vol. 142, Iss. 4, pp. 542-547
Open Access | Times Cited: 47
SOHO State of the Art Updates and Next Questions | Novel Immunotherapy Combinations for the Treatment of Indolent B-Cell Lymphoma
Tony Zhuang, Chen Zhang, Paolo Strati
Clinical Lymphoma Myeloma & Leukemia (2025)
Closed Access
A large colonic polyp: an atypical presentation of follicular lymphoma
Abraam Rezkalla, Islam Rajab, Nagihan Orhun, et al.
Journal of Surgical Case Reports (2025) Vol. 2025, Iss. 2
Open Access
Benign, Premalignant, and Malignant Duodenal Neoplasms
Matthew C. Hernandez, Paul Wong, Laleh G. Melstrom
(2025), pp. 173-188
Closed Access
Pathogenesis of follicular lymphoma
Tracy Lackraj, Rashmi S. Goswami, Robert Kridel
Best Practice & Research Clinical Haematology (2017) Vol. 31, Iss. 1, pp. 2-14
Open Access | Times Cited: 47
PI3K Inhibitors and Their Role as Novel Agents for Targeted Therapy in Lymphoma
Vladimir Sapon-Cousineau, Sasha Sapon-Cousineau, Sarit Assouline
Current Treatment Options in Oncology (2020) Vol. 21, Iss. 6
Closed Access | Times Cited: 34
Matching-adjusted indirect comparison of efficacy and safety of lisocabtagene maraleucel and mosunetuzumab for the treatment of third-line or later relapsed or refractory follicular lymphoma
Loretta J. Nastoupil, Ashley Bonner, Pearl Wang, et al.
Experimental Hematology and Oncology (2025) Vol. 14, Iss. 1
Open Access
Page 1 - Next Page

Scroll to top